Search Results 521-530 of 18367 for alopecia

1. Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment - Mayo Clinic

   - Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia ...

2. A Study to Evaluate AZD1775 in Women with Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma - Mayo Clinic

   investigator. 2. With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events ...

3. Study of Canakinumab in Patients With Myelofibrosis - Mayo Clinic

   excluding alopecia. - Women of childbearing potential (WCBP) must have a negative urine or serum pregnancy test within 28 days of starting the study drug ...

4. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

   Adverse events due to previous anti-tumor therapy have not recovered to ≤ CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤ CTCAE Grade 2.

5. Betamethasone dipropionate (topical application route) - Side effects & dosage - Mayo Clinic

   Betamethasone topical spray is used to treat adults with mild to moderate plaque psoriasis. This medicine is a corticosteroid (cortisone-like medicine or ...

6. Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) - Mayo Clinic

   Participants with alopecia, stable immune-related toxicity such as hypothyroidism on hormone replacement, adrenal insufficiency treated with ≤10 mg daily ...

7. Publications - Timothy D. Malouff, M.D. - Mayo Clinic

   Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PLoS One. 2013; 8 (7):e69368 Epub 2013 July 19. View PubMed. PST-20566501. Home ...

8. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases - Mayo Clinic

   ... alopecia and =< grade 2 neuropathy, which are allowed; Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion ...

9. A Study to Test the Addition of Nivolumab to Chemotherapy to Treat Soft Tissue Sarcoma - Mayo Clinic

   ... alopecia. Taxane Naive Patients Only: No prior exposure to taxane therapy of any duration for angiosarcoma. Taxane Pre-treated Patients Only: Prior taxane ...

10. Sym021 in Combination with Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients with Advanced Biliary Tract Carcinomas - Mayo Clinic

    ... alopecia not requiring systemic treatment, conditions not expected to recur in the absence of an external trigger. Patients with a history of organ ...